Avanafil (BioDeep_00000752567)
代谢物信息卡片
化学式: C23H26ClN7O3 (483.1785556000001)
中文名称: 阿伐那非
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl
InChI: InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
描述信息
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:66876
- KEGGdrug: D03217
- PubChem: 9869929
- DrugBank: DB06237
- ChEMBL: CHEMBL1963681
- CAS: 330784-47-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Giuseppe Derosa, Angela D'Angelo, Paola Stefania Preti, Pamela Maffioli. Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, Vitis vinifera L. and Ginkgo biloba, Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.
Frontiers in endocrinology.
2022; 13(?):847240. doi:
10.3389/fendo.2022.847240. [PMID: 35464055] - Xiuhua Ren, Hengyi Yu, Xingxing Qi, Qian Chen, Jingwen Yang, Yinian Fang, Yongfang Lei, Donglin Zhang, Qin Zuo, Dong Liu. A Bioequivalence Study of Avanafil in Healthy Chinese Male Subjects Under Fasting and Fed Conditions: Results of a Randomized, Open-Label, Single-Dose, 2-Sequence, 2-Period Crossover Study.
Clinical pharmacology in drug development.
2021 12; 10(12):1495-1502. doi:
10.1002/cpdd.998. [PMID: 34288578] - Abdelaal M Elkamshoushi, Noha M Badae, Mohamed G Kabary, Shaimaa I Omar. Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction.
Andrologia.
2021 Feb; 53(1):e13833. doi:
10.1111/and.13833. [PMID: 33112433] - Ahmed M Abdel-Raoof, Ragab A M Said, Mohamed S Emara, Ebrahim A El-Desouky, Ahmed M Abdelzaher, Mohamed A Hasan, Ayman E Osman. D-optimal design as a useful tool response surface methodology for the optimization of signals from synchronous fluorescence prior to simultaneous determination of avanafil and tadalafil.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2020 Jul; 235(?):118313. doi:
10.1016/j.saa.2020.118313. [PMID: 32251891] - Elif Öztürk Er, Belma Özbek, Sezgin Bakırdere. Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions.
Journal of separation science.
2019 Jan; 42(2):475-483. doi:
10.1002/jssc.201800734. [PMID: 30358113] - Hongbo Zheng, Yifeng Wu, Bin Sun, Chuanle Cheng, Yanan Qiao, Yuehua Jiang, Shengtian Zhao, Zhiyu Xie, Jing Tan, Hongxiang Lou. Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.
European journal of medicinal chemistry.
2018 Oct; 158(?):767-780. doi:
10.1016/j.ejmech.2018.09.028. [PMID: 30245400] - Mallesh Kurakula, Osama A A Ahmed, Usama A Fahmy, Tarek A Ahmed. Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies.
Journal of liposome research.
2016 Dec; 26(4):288-96. doi:
10.3109/08982104.2015.1117490. [PMID: 26784833] - Usama A Fahmy, Osama A A Ahmed, Khaled M Hosny. Development and evaluation of avanafil self-nanoemulsifying drug delivery system with rapid onset of action and enhanced bioavailability.
AAPS PharmSciTech.
2015 Feb; 16(1):53-8. doi:
10.1208/s12249-014-0199-3. [PMID: 25168449] - Mark Sanford. Avanafil: a review of its use in patients with erectile dysfunction.
Drugs & aging.
2013 Oct; 30(10):853-62. doi:
10.1007/s40266-013-0112-x. [PMID: 23955441] - Roberto Bruzziches, Davide Francomano, Pietro Gareri, Andrea Lenzi, Antonio Aversa. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Expert opinion on pharmacotherapy.
2013 Jul; 14(10):1333-44. doi:
10.1517/14656566.2013.799665. [PMID: 23675780] - George T Kedia, Stefan Uckert, Farhang Assadi-Pour, Markus A Kuczyk, Knut Albrecht. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Therapeutic advances in urology.
2013 Feb; 5(1):35-41. doi:
10.1177/1756287212466282. [PMID: 23372609] - Wayne J G Hellstrom, Matthew T Freier, Ege Can Serefoglu, Ronald W Lewis, Karen DiDonato, Craig A Peterson. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction.
BJU international.
2013 Jan; 111(1):137-47. doi:
10.1111/j.1464-410x.2012.11267.x. [PMID: 22788525] - Jinah Jung, Sangmin Choi, Sang Heon Cho, Jong-Lyul Ghim, Aekyung Hwang, Unjib Kim, Bong Sik Kim, Atsushi Koguchi, Shinji Miyoshi, Hirotaka Okabe, Kyun-Seop Bae, Hyeong-Seok Lim. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Clinical therapeutics.
2010 Jun; 32(6):1178-87. doi:
10.1016/j.clinthera.2010.06.011. [PMID: 20637970]